1. Yosipovitch G, Greaves M: Defintions of Itch. In: Itch: Basic Mechanisms and Therapy, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, pp. 1-4
2. Davidson S, Giesler GJ: The multiple pathways for itch and their interaction with pain. Trends Neurosci 33(12):550-558, 2010
3. Yosipovitch G, Carstens E, McGlone F: Chronic itch and chronic pain: Analogous mechanisms. Pain 131(1-2):4-7, 2007
4. Patel T, Yosipovitch G: Therapy of pruritus. Expert Opin Pharmacother 11(10):1673-1682, 2010
5. Weisshaar E, Dalgard F: Epidemiology of itch: Adding to the burden of skin morbidity. Acta Derm Venereol 89(4):339-350, 2009
6. Dalgard F et al: Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol 151(2):452-457, 2004
7. Yosipovitch G et al: Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 147(1):32-36, 2002
8. Van Loey NE et al: Itching following burns: Epidemiology and predictors. Br J Dermatol 158(1):95-100, 2008
9. Lim YL et al: Pruritus is a common and significant symptom of acne. J Eur Acad Dermatol Venereol 22(11):1332-1336, 2008
10. Reich A et al: Acne itch: Do acne patients suffer from itching? Acta Derm Venereol 88(1):38-42, 2008
11. Razykov I et al: Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Rheum 61(12):1765-1770, 2009
12. Makunde WH et al: Clinical and parasitological aspects of itching caused by onchocerciasis in Morogoro, Tanzania. Ann Trop Med Parasitol 94:793-799, 2000
13. Hicks MI, Elston DM: Scabies. Dermatol Ther 22(4):279-292, 2009
14. Stander S et al: Clinical classification of itch: A position paper of the International Forum for the Study of Itch. Acta Derm Venereol 87(4):291-294, 2007
15. Yosipovitch G et al: The brain processing of scratching. J Invest Dermatol 128(7):1806-1811, 2008
16. Shelley WB, Arthur RP: The neurohistology and neurophysiology of the itch sensation in man. AMA Arch Derm 76(3):296-323, 1957
17. Hilliges M, Wang L, Johansson O: Ultrastructural evidence for nerve fibers within all vital layers of the human epidermis. J Invest Dermatol 104(1):134-137, 1995
18. Liu Q et al: Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139(7):1353-1365, 2009
19. Yosipovitch G: The pruritus receptor unit: A target for novel therapies. J Invest Dermatol 127(8):1857-1859, 2007
20. Inoue K et al: Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 291(1):124-129, 2002
21. Schmelz M et al: Specific C-receptors for itch in human skin. J Neurosci 17(20):8003-8008, 1997
22. Fruhstorfer H, Hermanns M, Latzke L: The effects of thermal stimulation on clinical and experimental itch. Pain 24(2):259-269, 1986
23. Schmelz M et al: Active “itch fibers” in chronic pruritus. Neurology 61(4):564-566, 2003
24. Schmelz M et al: Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 89(5):2441-2448, 2003
25. Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch. Nat Neurosci 4(1):72-77, 2001
26. Ikoma A et al: Painful stimuli evoke itch in patients with chronic pruritus: Central sensitization for itch. Neurology 62(2):212-217, 2004
27. Ikoma A et al: Electrically evoked itch in humans. Pain 113(1-2):148-154, 2005
28. Ishiuji Y et al: Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis. Br J Dermatol 158(1):78-83, 2008
29. Davidson S et al: The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 27(37):10007-10014, 2007
30. Namer B et al: Separate peripheral pathways for pruritus in man. J Neurophysiol 100(4):2062-2069, 2008
31. Reddy VB et al: Cowhage-evoked itch is mediated by a novel
cysteine protease: A ligand of protease-activated receptors.
J Neurosci 28(17):4331-4335, 2008
32. Sun YG et al: Cellular basis of itch sensation. Science 325(5947):1531-1534, 2009
33. Darsow U et al: New aspects of itch pathophysiology: Component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol 124(1-3):326-331, 2001
34. Yosipovitch G: Itch questionnaires as tools for itch evaluation. In: Itch: Basic Mechanisms and Therapy, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, p. 169
35. Yosipovitch G et al: Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 41(4):212-216, 2002
36. Ishiuji Y et al: Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis. Br J Dermatol 161(5):1072-1080, 2009
37. Mochizuki H et al: Time course of activity in itch-related brain regions: A combined MEG-fMRI study. J Neurophysiol 102(5):2657-2666, 2009
38. Stander S et al: Neurophysiology of pruritus: Cutaneous elicitation of itch. Arch Dermatol 139(11):1463-1470, 2003
39. Davies MG, Greaves MW: Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol 9(5):461-465, 1980
40. Greaves M, Shuster S: Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. J Physiol 193(2):255-267, 1967
41. Sugimoto Y et al: Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy 34(3):456-459, 2004
42. Cowden JM, Zhang M, Dunford PJ, Thurmond RL: The histamine H(4) receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 130(4):1023-1033, 2010
43. Rossbach K et al: Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 18(1):57-63, 2009
44. Steinhoff M et al: Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6(2):151-158, 2000
45. Luger TA: Neuromediators—A crucial component of the skin immune system. J Dermatol Sci 30(2):87-93, 2002
46. Shimada SG, Shimada KA, Collins JG: Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. Eur J Pharmacol 530(3):281-283, 2006
47. Tsujii K et al: Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. J Pharmacol Sci 108(3):385-388, 2008
48. Steinhoff M et al: Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci 23(15):6176-6180, 2003
49. Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA: Cathepsin S elicits itch and signals via protease-activated receptors. J Invest Dermatol 130(5):1468-1470, 2010
50. Grobe K et al: Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of
cysteine proteinases.
Eur J Biochem 269(8):2083-2092, 2002
51. Heyer G et al: Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol 75(5):348-352, 1995
52. Rukwied R, Heyer G: Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and
acetylcholine in atopic eczema patients and healthy controls.
Arch Dermatol Res 290(4):198-204, 1998
53. Wahlgren CF: Measurement of itch. Semin Dermatol 14(4):277-284, 1995
54. Toyoda M et al: Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 147(1):71-79, 2002
55. Schmelz M et al: Mast cell tryptase in dermal neurogenic inflammation. Clin Exp Allergy 29(5):695-702, 1999
56. Weidner C et al: Acute effects of substance P and
calcitonin gene-related peptide in human skin—A microdialysis study.
J Invest Dermatol 115(6):1015-1020, 2000
57. Suzuki R et al: Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 163(5):2410-2415, 1999
58. Cocchiara R et al: Mast cell production of TNF-alpha induced by substance P evidence for a modulatory role of substance P-antagonists. J Neuroimmunol 101(2):128-136, 1999
59. Imamachi N et al: TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A 106(27):11330-11335, 2009
60. Shim WS et al: TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 27(9):2331-2337, 2007
61. Yoshioka T et al: Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. J Invest Dermatol 129(3):714-722, 2009
62. Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448(7154):700-703, 2007
63. Fjellner B, Hagermark O: Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and
morphine.
Arch Dermatol Res 274:(1-2):29-37, 1982
64. Bernstein JE, Swift R: Relief of intractable pruritus with
naloxone.
Arch Dermatol 115(11):1366-1367, 1979
65. Fjellner B, Hagermark O: The influence of the opiate antagonist
naloxone on experimental pruritus.
Acta Derm Venereol 64(1):73-75, 1984
66. Hagermark O: Peripheral and central mediators of itch. Skin Pharmacol 5(1):1-8, 1992
67. Bergasa NV: An approach to the management of the pruritus of cholestasis. Clin Liver Dis 8(1):55-66, vi, 2004
68. Togashi Y et al: Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435:(2-3):259-264, 2002
69. Umeuchi H et al: Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 477(1):29-35, 2003
70. Yosipovitch G et al: Itch. Lancet 361(9358):690-694, 2003
71. Pan ZZ: mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 19(3):94-98, 1998
72. Bigliardi PL et al: Opioids and the skin—Where do we stand? Exp Dermatol 18(5):424-430, 2009
73. Mendell LM, Albers KM, Davis BM: Neurotrophins, nociceptors, and pain. Microsc Res Tech 45(4-5):252-261, 1999
74. Nakamura M, Toyoda M, Morohashi M: Pruritogenic mediators in psoriasis vulgaris: Comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 149(4):718-730, 2003
75. Raychaudhuri SP, Raychaudhuri SK: Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 146:433-437, 2004
76. Groneberg DA et al: Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol 161:(1-2):87-92, 2005
77. Grewe M et al: Neurotrophin-4 production by human epidermal keratinocytes: Increased expression in atopic dermatitis. J Invest Dermatol 114(6):1108-1112, 2000
78. Sonkoly E et al: IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411-417, 2006
79. Arita K et al: Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet 82(1):73-80, 2008
80. Grimstad O et al: Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp Dermatol 18(1):35-43, 2009
81. Hagermark O, Strandberg K, Hamberg M: Potentiation of itch and flare responses in human skin by prostaglandins E2 and H2 and a prostaglandin endoperoxide analog. J Invest Dermatol 69(6):527-530, 1977
82. Hagermark O, Strandberg K: Pruritogenic activity of prostaglandin E2. Acta Derm Venereol 57(1):37-43, 1977
83. Greaves MW, McDonald-Gibson W: Itch: Role of prostaglandins. Br Med J 3(5881):608-609, 1973
84. Daly BM, Shuster S: Effect of
aspirin on pruritus.
Br Med J (Clin Res Ed) 293(6552):907, 1986
85. Yosipovitch G et al: The effect of topically applied
aspirin on localized circumscribed neurodermatitis.
J Am Acad Dermatol 45(6):910-913, 2001
86. Arai I et al: Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 505:(1-3):229-235, 2004
87. Sugimoto M et al: Putative mechanism of the itch-scratch circle: Repeated scratching decreases the cutaneous level of prostaglandin D2, a mediator that inhibits itching. Prostaglandins Leukot Essent Fatty Acids 76(2):93-101, 2007
88. Andoh T et al: Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J Invest Dermatol 127(8):2042-2047, 2007
89. Dawn A et al: Itch characteristics in atopic dermatitis: Results of a web-based questionnaire. Br J Dermatol 160(3):642-644, 2009
90. Yosipovitch G et al: The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 143(5):969-973, 2000
91. Pisoni RL et al: Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21(12):3495-3505, 2006
92. Yosipovitch G, Papoiu AD: What causes itch in atopic dermatitis? Curr Allergy Asthma Rep 8(4):306-311, 2008
93. Krause L, Shuster S: Mechanism of action of antipruritic drugs. Br Med J (Clin Res Ed) 287(6400):1199-1200, 1983
94. Anderzen I et al: Stress and sensitization in children: A controlled prospective psychophysiological study of children exposed to international relocation. J Psychosom Res 43(3):259-269, 1997
95. Arnetz BB et al: Endocrine and dermatological concomitants of mental stress. Acta Derm Venereol Suppl (Stockh) 156:9-12, 1991
96. Ehlers A et al: Atopic dermatitis and stress: Possible role of negative communication with significant others. Int J Behav Med 1(2):107-121, 1994
97. Arndt J, Smith N, Tausk F: Stress and atopic dermatitis. Curr Allergy Asthma Rep 8(4):312-317, 2008
98. Bigliardi PL et al: Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 56(6):979-988, 2007
99. Bigliardi-Qi M et al: Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 210(2):91-99, 2005
100. Ersser SJ, Surridge H, Wiles A: What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract 8(4):367-376, 2002
101. Krueger G et al: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280-284, 2001
102. Sampogna F et al: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 151(3):594-599, 2004
103. van de Kerkhof PC et al: Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 197(4):326-334, 1998
104. van de Kerkhof PC et al: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 200(4):292-298, 2000
105. Dawn A, Yosipovitch G: Treating itch in psoriasis. Dermatol Nurs 18(3):227-233, 2006
106. Oaklander AL et al: Herpes zoster itch: Preliminary epidemiologic data. J Pain 4(6):338-343, 2003
107. Wood GJ et al: An insatiable itch. J Pain 10(8):792-797, 2009
108. Walcyk PJ, Elpern DJ: Brachioradial pruritus: A tropical dermopathy. Br J Dermatol 115(2):177-180, 1986
109. Wallengren J: Brachioradial pruritus: A recurrent solar dermopathy. J Am Acad Dermatol 41(4):657-658, 1999
110. Binder A et al: A case of neuropathic brachioradial pruritus caused by cervical disc herniation. Nat Clin Pract Neurol 4(6):338-342, 2008
111. Lane JE, McKenzie JT, Spiegel J: Brachioradial pruritus: A case report and review of the literature. Cutis 81(1):37-40, 2008
112. Eisenberg E, Barmeir E, Bergman R: Notalgia paresthetica associated with nerve root impingement. J Am Acad Dermatol 37(6):998-1000, 1997
113. Yosipovitch G, Samuel LS: Neuropathic and psychogenic itch. Dermatol Ther 21(1):32-41, 2008
114. Narita I et al: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69(9):1626-1632, 2006
115. Gilchrest BA et al: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 91(1):17-21, 1979
116. Kuypers DR et al: A prospective proof of concept study of the efficacy of
tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy.
Nephrol Dial Transplant 19(7):1895-1901, 2004
117. Silva SR et al:
Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial.
Nephron 67(3):270-273, 1994
118. Patel TS, Freedman BI, Yosipovitch G: An update on pruritus associated with CKD. Am J Kidney Dis 50(1):11-20, 2007
119. Kumagai H et al: Prospects for a novel -opioid receptor agonist, TRK-820, in uremic pruritus. In: Itch: Basic Mechanisms and Therapy, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, pp. 279-286
120. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H: Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25(4):1251-1257, 2010
121. Wikstrom B et al: Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16(12):3742-3747, 2005
122. Carmichael AJ et al: Serological markers of renal itch in patients receiving long term haemodialysis. Br Med J (Clin Res Ed) 296(6636):1575, 1988
123. Hampers CL et al: Disappearance of “uremic” itching after subtotal parathyroidectomy. N Engl J Med 279(13):695-697, 1968
124. Wang H, Yosipovitch G: New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 49:1-11, 2010
125. Ghent CN, Bloomer JR, Klatskin G: Elevations in skin tissue levels of bile acids in human cholestasis: Relation to serum levels and topruritus. Gastroenterology 73(5):1125-1130, 1977
126. Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. BMJ 297(6662):1501-1504, 1988
127. Bergasa NV et al: Effects of
naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.
Ann Intern Med 123(3):161-167, 1995
128. Bergasa NV et al: Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 53(16):1253-1257, 1993
129. Bergasa NV et al: A controlled trial of
naloxone infusions for the pruritus of chronic cholestasis.
Gastroenterology 102(2):544-549, 1992
130. Bergasa NV et al: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 268(2 Pt 1):G346-G354, 1995
131. Bergasa NV et al: Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 20(1):85-90, 1994
132. Oude Elferink RP et al: The molecular mechanism of cholestatic pruritus. Dig Dis 29(1):66-71, 2011
133. Caravati CM Jr et al: Cutaneous manifestations of hyperthyroidism. South Med J 62(9):1127-1130, 1969
134. Neilly JB et al: Pruritus in diabetes mellitus: Investigation of prevalence and correlation with diabetes control. Diabetes Care 9(3):273-275, 1986
135. Scribner M: Diabetes and pruritus of the scalp. JAMA 237(15):1559, 1977
136. Ross DR, Varipapa RJ: Treatment of painful diabetic neuropathy with topical
capsaicin.
N Engl J Med 321(7):474-475, 1989
137. Yamaoka H et al: Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes Care 33(1):150-155, 2010
138. Gilbert HS, Warner RR, Wasserman LR: A study of histamine in myeloproliferative disease. Blood 28(6):795-806, 1966
139. Archer CB, Camp RD, Greaves MW: Polycythaemia vera can present with aquagenic pruritus. Lancet 1(8600):1451, 1988
140. Botero F: Pruritus as a manifestation of systemic disorders. Cutis 21(6):873-880, 1978
141. Ishii T et al: Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113(23):5942-5950, 2009
142. Yosipovitch G: Chronic Pruritus: A Paraneoplastic Sign. Dermatol Ther 23(6):590-596, 2010
143. Kantor GR, Lookingbill DP: Generalized pruritus and systemic disease. J Am Acad Dermatol 9(3):375-382, 1983
144. Paul R, Paul R, Jansen CT: Itch and malignancy prognosis in generalized pruritus: A 6-year follow-up of 125 patients. J Am Acad Dermatol 16(6):1179-1182, 1987
145. Duque MI, Yosipovitch G, Pegram S: Itch in HIV-infected patients. In: G Yosipovitch, M Greaves, AB Fleischer Jr, F McGlone. Itch: Basic Mechanisms and Therapy. New York, Marcel Dekker, 2004, p. 219
146. Mazeh D et al: Itching in the psychiatric ward. Acta Derm Venereol 88(2):128-131, 2008
147. Kretzmer GE et al: Idiopathic pruritus in psychiatric inpatients: An explorative study. Gen Hosp Psychiatry 30(4):344-348, 2008
148. Beauregard S, Gilchrest BA: A survey of skin problems and skin care regimens in the elderly. Arch Dermatol 123(12):1638-1643, 1987
149. Patel T, Yosipovitch G: The management of chronic pruritus in the elderly. Skin Therapy Lett 15(8):5-9, 2010
150. Ward JR, Bernhard JD: Willan's itch and other causes of pruritus in the elderly. Int J Dermatol 44(4):267-273, 2005
151. Ward RS et al: Substance P axons and sensory threshold increase in burn-graft human skin. J Surg Res 118(2):154-160, 2004
152. Lee SS et al: Pruritus, pain, and small nerve fiber function in keloids: A controlled study. J Am Acad Dermatol 51(6):1002-1006, 2004
153. Shelley WB, Rawnsley HM: Aquagenic urticaria. Contact sensitivity reaction to water. JAMA 189:895-898, 1964
154. Greaves MW et al: Aquagenic pruritus. Br Med J (Clin Res Ed) 282(6281):2008-2010, 1981
155. Gambichler T et al: A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 31(3):348-353, 2006
156. McGrath JA, Greaves MW: Aquagenic pruritus and the myelodysplastic syndrome. Br J Dermatol 123(3):414-415, 1990
157. Yosipovitch G, Fast K, Bernhard JD: Noxious heat and scratching decrease histamine-induced itch and skin blood flow. J Invest Dermatol 125(6):1268-1272, 2005
158. Elias PM, Schmuth M: Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 9(4):265-272, 2009
159. Stander S et al: Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2(2):213-218, 2006
160. Senba E et al: The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 50(3):257-262, 2004
161. Peier AM et al: A TRP channel that senses cold stimuli and menthol. Cell 108(5):705-715, 2002
162. Patel T, Ishiuji Y, Yosipovitch G: Menthol: A refreshing look at this ancient compound. J Am Acad Dermatol 57(5):873-878, 2007
163. Yosipovitch G et al: Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. Arch Dermatol Res 288(5-6):245-248, 1996
164. Papoiu AD, Yosipovitch G: Topical
capsaicin. The fire of a “hot” medicine is reignited.
Expert Opin Pharmacother 11(8):1359-1371, 2010
165. Weisshaar E et al: Effect of topical
capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin.
Arch Dermatol Res 290(6):306-311, 1998
166. Young TA et al: A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatol Treat 20(2):76-81, 2009
167. Yosipovitch G, Maibach HI: Effect of topical
pramoxine on experimentally induced pruritus in humans.
J Am Acad Dermatol 37(2 Pt 1):278-280, 1997
168. Freitag G, Hoppner T: Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 13(9):529-537, 1997
169. Drake LA, Fallon JD, Sober A: Relief of pruritus in patients with atopic dermatitis after treatment with topical
doxepin cream. The
Doxepin Study Group.
J Am Acad Dermatol 31(4):613-616, 1994
170. Szepietowski JC, Reich A, Szepietowski T:
Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options.
Ther Apher Dial 9(3):277-279, 2005
171. Peer G et al: Randomised crossover trial of
naltrexone in uraemic pruritus.
Lancet 348(9041):1552-1554, 1996
172. Wolfhagen FH et al: Oral
naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study.
Gastroenterology 113(4):1264-1269, 1997
173. Terg R et al: Efficacy and safety of oral
naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.
J Hepatol 37(6):717-722, 2002
174. Metze D et al: Efficacy and safety of
naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.
J Am Acad Dermatol 41(4):533-539, 1999
175. Bailey AG et al: Epidural
morphine combined with epidural or intravenous
butorphanol for postoperative analgesia in pediatric patients.
Anesth Analg 79(2):340-344, 1994
176. Gunter JB et al: Continuous epidural
butorphanol relieves pruritus associated with epidural
morphine infusions in children.
Paediatr Anaesth 10(2):167-172, 2000
177. Dawn AG, Yosipovitch G:
Butorphanol for treatment of intractable pruritus.
J Am Acad Dermatol 54(3):527-531, 2006
178. Davis MP et al:
Mirtazapine for pruritus.
J Pain Symptom Manage 25(3):288-291, 2003
179. Hundley JL, Yosipovitch G:
Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: A pilot study.
J Am Acad Dermatol 50(6):889-891, 2004
180. Stander S et al: Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors
paroxetine and
fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study.
Acta Derm Venereol 89(1):45-51, 2009
181. Ehrchen J, Stander S:
Pregabalin in the treatment of chronic pruritus.
J Am Acad Dermatol 58(2 Suppl.):S36-S37, 2008
182. Duval A, Dubertret L:
Aprepitant as an antipruritic agent?
N Engl J Med 361(14):1415-1416, 2009
183. Nilsson HJ, Levinsson A, Schouenborg J: Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 71(1):49-55, 1997
184. Wallengren J, Sundler F: Cutaneous field stimulation in the treatment of severe itch. Arch Dermatol 137(10):1323-1325, 2001
185. Pfab F, Huss-Marp J, Gatti A et al: Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema—a blinded, randomized, placebo-controlled, crossover trial. Allergy 65(7):903-910, 2010
186. Pfab F et al: Preventive effect of acupuncture on histamine-induced itch: A blinded, randomized, placebo-controlled, crossover trial. J Allergy Clin Immunol 116(6):1386-1388, 2005
187. Yamamoto Y et al: Association between frequency of pruritic symptoms and perceived psychological stress: A Japanese population-based study. Arch Dermatol 145(12):1384-1388, 2009
188. Gieler U et al: Psychosomatic aspects of pruritus. In: Itch: Basic Mechanisms and Therapy, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, p. 343
189. Tran BW, Papoiu AD, Russoniello CV, Wang H, Patel TS, Chan YH, Yosipovitch G: The Effect of itch, scratching and mental stress on autonomic nervous system in atopic eczema. Acta Derm Venereol 90(4):354-361, 2010
190. van Os-Medendorp H et al: Effectiveness of the nursing programme ‘Coping with itch’: A randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 156(6):1235-1244, 2007